SANUWAVE Health, Inc. (SNWV) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals several negative aspects, including a miss on Q3 revenue guidance, market uncertainty impacting growth, and challenges in forecasting. Despite some positive developments like a record September revenue and improved sales pipeline, the downward adjustment of annual revenue guidance and regulatory risks weigh heavily. The Q&A section reflects cautious optimism but lacks specific details, and the refusal to provide detailed guidance further dampens sentiment. These factors suggest a likely stock price decline in the range of -2% to -8%.
Key Financial Performance
Q3 2025 Revenue $11.4 million to $11.6 million, representing 12% to 14% sequential growth from Q2 and 22% to 24% growth year-over-year. Reasons for the increase include a record number of system sales and improved business flow later in the quarter, particularly after the SAWC convention in September.
September 2025 Revenue Best single month in company history for revenue, system sales, and applicators. This improvement was attributed to the amelioration of market uncertainty and increased business activity after the SAWC convention.
Annual Revenue Guidance Adjustment Adjusted to $44 million to $46 million, approximately 40% year-over-year growth at midpoint. The adjustment was due to a slower-than-expected start to Q3 caused by market uncertainty related to proposed reimbursement changes for skin substitute and allograft products.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
UltraMIST reimbursement: Proposed changes in reimbursement for UltraMIST are minimal, with an increase of $2 to $4, which is considered a positive outcome in the wound care market.
Revenue growth: Q3 2025 revenue reached $11.4M to $11.6M, a record for the company, with 12%-14% sequential growth from Q2 and 22%-24% growth year-over-year.
Annual revenue guidance adjustment: Annual revenue guidance was revised to $44M-$46M, reflecting approximately 40% year-on-year growth, down from the prior guidance of $48M-$50M.
Market uncertainty impact: Uncertainty around reimbursement changes for skin substitute and allograft products slowed market activity, affecting growth plans and capital budgets.
Sales team expansion: 10 out of 13 salespeople joined since November, contributing to a robust pipeline and increased business activity.
September performance: September was the best month in company history for revenue, system sales, and applicators, despite a slow start to Q3.
Market positioning opportunity: The company sees potential to expand its footprint and partnerships as the wound care market stabilizes post-reimbursement uncertainty.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Revenue Guidance Miss: The company did not meet its previously announced Q3 revenue guidance of $12 million to $12.7 million, achieving only $11.4 million to $11.6 million. This shortfall has led to a downward adjustment in annual revenue guidance from $48 million to $50 million to $44 million to $46 million.
Market Uncertainty: Proposed changes in reimbursement for skin substitute and allograft products created uncertainty in the wound care market, causing delays in growth plans, capital budgets, and patient counts. This uncertainty froze market activity, particularly in the early part of Q3.
Sales Team Ramp-Up: 10 out of 13 salespeople joined the company since last November, and while they are building a robust pipeline, delays and uncertainty in deal closures have impacted the company's ability to meet revenue expectations.
Forecasting Challenges: The company faced challenges in accurately forecasting the resolution of market disruptions and the timing of deal closures, which contributed to the revenue shortfall.
Regulatory Risks: Uncertainty around the finalization of reimbursement changes for skin substitute products has created a challenging environment for planning and market activity. Although the company does not expect these changes to materially affect UltraMIST, the broader market impact remains a concern.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Annual Revenue Guidance Adjustment: The company has adjusted its annual revenue guidance to $44 million to $46 million, representing approximately 40% year-on-year growth at the midpoint. This is a reduction from the prior guidance of $48 million to $50 million.
Market Conditions and Reimbursement Changes: Uncertainty in the wound care market, driven by proposed changes in reimbursement for skin substitute and allograft products, has impacted growth plans, capital budgets, and patient counts. However, the company does not believe these changes will materially affect reimbursement for UltraMIST.
Future Market Opportunities: The company sees substantial opportunities to expand its footprint and partnerships as the market adjusts to reimbursement changes. Revenue and business flow showed improvement in September, indicating a potential resolution of market uncertainties.
Sales Team and Pipeline Development: The company is in a ramp-up phase with 10 of 13 salespeople joining since last November. The sales pipeline is described as robust and the best it has ever been, though delays and uncertainties have impacted deal closures and implementation timelines.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you provide more details on the revenue number, particularly the mix or the number of capital equipment sales in the quarter?
A:We placed 155 systems in the quarter.
Q:Did the momentum in September, particularly after SAWC, contribute to the rebound? Do you feel the momentum is continuing into Q4?
A:It seems like the SAWC conference reduced the perception of uncertainty in the industry, leading to a significant uptick in business and traction. While it's early in Q4, there are no signs of slowing down yet.
Q:Which sites of care have been the most active, and are there areas that could be key growth drivers?
A:Mobile clinics have been a big driver, with growth also seen in wound centers and hospitals. The hospital-acquired pressure injuries (HAPI) market, estimated at $22 billion in the U.S., is a key focus area due to its impact on patient quality of life and hospital costs.
Q:Is the split between diabetic foot ulcers (DFU) and venous blood ulcers (VLU) still roughly the same?
A:It's hard to say as the company does not have visibility into the specific types of wounds being treated by providers.
Q:Can you provide an update on the pipeline and any other relevant details?
A:The company is focusing on engaging with larger, higher-use customers and expects to see research papers and posters from these groups in the coming months. Some deals are taking longer to close, but the pipeline remains strong.
Q:Was the CMS disruption more of an issue for smaller or larger customers?
A:There was no significant distinction; the disruption seemed general across customers using skin substitutes.
Q:If the PFS and OPPS proposals are adopted, could this create a need for an additional revenue line for healthcare providers?
A:Yes, it could create an opportunity to establish evidence-based protocols and best practices for wound care, which could benefit the company.
Q:What visibility does the company have regarding the Q4 ramp implied by the guidance?
A:The company has a great deal of visibility but prefers to remain cautious with its guidance.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the split between DFU and VLU treatments, citing a lack of visibility into the types of wounds being treated. Additionally, they refrained from discussing specifics about the pipeline and individual customers, opting to speak in general terms.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
CEO preface
Frank CEO
Instructions pleasure
Instructions today
Morgan Frank
SANUWAVE Update
Update Instructions
conference Morgan
day SANUWAVE
market record
pleasure today
preface revenue
revenue today
today Instructions
today conference
today market
SNWV Transcript
SANUWAVE Health, Inc. (SNWV) Q1 2026 Earnings Call Transcript
Unknown5-13
Despite a slight revenue increase and optimistic guidance, the company's financial health is concerning due to increased operating expenses, a decline in gross margin, and extended sales cycles. The Q&A reveals confidence in future growth but lacks specifics on product advancements and market expansion. The transition to wholesale pricing and sales tax exposure add further risk. Overall, the financial metrics and uncertainties suggest a negative stock price movement in the short term.
SANUWAVE Health, Inc. (SNWV) Q4 2025 Earnings Call Transcript
Positive3-27
The earnings call highlights a strong financial performance with a 25% revenue increase, improved gross margins, and a shift from net loss to net income. The positive cash flow indicates solid financial health. Despite the absence of strategic and operational updates, the financial metrics suggest a positive outlook. However, the lack of strategic guidance and acknowledgment of risks tempers the sentiment slightly. The overall impact is likely positive, given the financial turnaround and margin improvements.
SANUWAVE Health, Inc. (SNWV) Q3 2025 Earnings Call Transcript
Positive11-7
The earnings call summary indicates a focus on cost efficiency, marketing expansion, and a conservative revenue guidance due to past anomalies. The Q&A section reveals positive sentiment towards sales strategies and potential growth, despite some uncertainties in adoption timelines. Key factors like improved financial footing and inbound interest from distributors suggest a positive outlook. However, the lack of international expansion and cautious revenue guidance temper expectations. Overall, the sentiment is positive, with a potential stock price increase of 2% to 8% over the next two weeks.
SANUWAVE Health, Inc. (SNWV) Q3 2025 Earnings Call Transcript
Unknown10-6
The earnings call reveals several negative aspects, including a miss on Q3 revenue guidance, market uncertainty impacting growth, and challenges in forecasting. Despite some positive developments like a record September revenue and improved sales pipeline, the downward adjustment of annual revenue guidance and regulatory risks weigh heavily. The Q&A section reflects cautious optimism but lacks specific details, and the refusal to provide detailed guidance further dampens sentiment. These factors suggest a likely stock price decline in the range of -2% to -8%.
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
